Loading stock data…
ATAI
$4.14-0.02 (-0.48%)
Market ClosedLast close May 1
AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
AtaiBeckley Inc. in the Healthcare sector is trading at $4.14. The stock is currently 39% below its 52-week high of $6.75, remaining 2.8% below its 200-day moving average. Technical signals show neutral RSI of 58 and bearish MACD signal, explaining why ATAI maintains its current current market pressure. The Whystock Score of 30/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 58) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$4.14
Potential Upside
5%
Whystock Fair Value$4.35
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus12 analysts
Mean target$14.00+238.2%
Range$7.00 – $25.00
Fundamentals
AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation o...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.72B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.57
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-297.49%
Volume
Today's trading volume
2.33M
Recent News
Does AtaiBeckley’s (ATAI) EMP-01 Data Hint At A Scalable MDMA Therapy Platform?
In April 2026, AtaiBeckley Inc. reported expanded Phase 2a data showing its oral R-MDMA candidate EMP-01 produced clinically meaningful, well-tolerated improvements in multiple symptom, functioning, and behavioral measures for adults with Social Anxiety Disorder, without severe or serious adverse events. Alongside symptom scale gains, nearly half of EMP-01 patients were rated as responders by both clinicians and patients by Day 43, suggesting perceived real-world benefits in everyday social...
These 3 Psychedelic Stocks Activated After Trump's Executive Order
Psychedelic drugs could get a big boost thanks to a recent executive order, and these firms all have promising candidates in line.
AtaiBeckley wins OVID Health Silver Award for patient partnership in psychedelic trials
AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) said on Monday it had received the Silver Award in OVID Health’s 2026 Patient Participant Index, recognizing its collaboration with the Psychedelic Participant Advocacy Network (PsyPAN) to strengthen participant involvement in psychedelic clinical...
FDA Fast-Tracks Review of Some Psychedelic Drugs. This Stock Is Set to Benefit.
Compass Pathways, the developer of synthetic psilocybin, announced it had received a government voucher.
Psychedelic Pharma Stocks Are Riding High. Past Cannabis Returns Are a Reality Check.
Shares of AtaiBeckley which is testing a nasal spray with an ayahuasca ingredient for depression, are up 212% in a year. Compass Pathways which is also working on depression with a lab-made compound of psilocybin, the stuff found naturally in magic mushrooms, is up 134%. There’s a new White House push to accelerate clinical reviews of psychedelics.